SCHEMBL25945989

SCHEMBL25945989

Cc1ccc(NC(=O)c2ccc(Cl)c(S(=O)(=O)[C@@H]3CC4CC[C@@H](C3)[C@]4(C)O)c2)cc1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
LMNA P02545 2/20 0.52
MAPK1 P28482 2/20 0.52
HTT P42858 2/20 0.52
MEN1 O00255 1/20 0.52
ALDH1A1 P00352 1/20 0.52
KMT2A Q03164 1/20 0.52
TP53 P04637 8/20 0.47
POLB P06746 1/20 0.46
KCNQ3 O43525 2/20 0.45
KCNQ2 O43526 2/20 0.45
KCNE1 P15382 2/20 0.45
KCNQ1 P51787 2/20 0.45
CNR2 P34972 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
THRB P10828 1/20 0.42
KCNQ5 Q9NR82 1/20 0.42
CNR1 P21554 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25949518 1.00 MAPT (0.52) MAPTSMN1; SMN2LMNAMAPK1HTT
SCHEMBL23127122 1.00 MAPT (0.52) MAPTSMN1; SMN2LMNAMAPK1HTT
SCHEMBL23127120 1.00 MAPT (0.52) MAPTSMN1; SMN2LMNAMAPK1HTT
SCHEMBL20779489 0.95 MAPT (0.52) MAPTSMN1; SMN2LMNAMAPK1HTT
SCHEMBL23127280 0.94 MAOB (0.47) MAPTSMN1; SMN2LMNAMAPK1HTT
SCHEMBL23127282 0.94 MAOB (0.47) MAPTSMN1; SMN2LMNAMAPK1HTT
SCHEMBL25949529 0.94 MAOB (0.47) MAPTSMN1; SMN2LMNAMAPK1HTT
SCHEMBL19351496 0.93 MAPT (0.45) MAPTSMN1; SMN2LMNAMAPK1HTT
SCHEMBL20642631 0.93 MAPT (0.45) MAPTSMN1; SMN2LMNAMAPK1HTT
SCHEMBL19319542 0.93 MAPT (0.45) MAPTSMN1; SMN2LMNAMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230241012-A1 HEPATITIS B ANTIVIRAL AGENTS ENANTA PHARM INC (US) 2023-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230241012-A1 HEPATITIS B ANTIVIRAL AGENTS HAVCR2, PYGL, SLC10A1 MAPT 4660/4885SMN1; SMN2 4765/4885LMNA 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.